Michael Weiss, TG Therapeutics CEO
January 27, 2022 01:50 PM ESTUpdated 02:01 PM
FDA+

Biotech gets burned at a fire­side chat as CEO re­veals FDA clamped a hold on its can­cer drug, now un­der re­view

John Carroll

Editor & Founder

A not-so-fun­ny thing hap­pened to TG Ther­a­peu­tics on its way to the ac­com­mo­da­tion re­view for its lead drug. The CEO re­vealed at an in­vest­ment con­fer­ence …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times